Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Ileana Corbeau, Simon Thezenas, Aurelie Maran-Gonzalez, Pierre-Emmanuel Colombo, William Jacot, Severine Guiu, Ileana Corbeau, Simon Thezenas, Aurelie Maran-Gonzalez, Pierre-Emmanuel Colombo, William Jacot, Severine Guiu

Abstract

Background: Inflammatory blood markers, such as neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR), have been reported as putative prognostic factors for survival and predictive factors for pathological complete response and toxicity in cancers, however with conflicting results.

Methods: We retrospectively analyzed data of 280 patients with early breast cancer receiving neo-adjuvant chemotherapy between 2005 and 2013 in our center. Neutrophil count, lymphocyte count and platelet count before treatment were collected as well as data on pathological complete response, toxicity, recurrence and survival.

Results: In multivariate analysis, high PLR was an independent prognostic factor for relapse-free survival (hazard ratio [HR] = 1.91; 95%CI = 1.15-3.16; p = 0.012) and for shorter overall survival (HR = 1.83; 95%CI = 1.03-3.24; p = 0.039). NLR was an independent predictive factor for febrile neutropenia (HR = 0.28; 95%CI = 0.13-0.58; p = 0.001). In triple negative breast cancer molecular subtype, low white blood cell count (<6.75 G/L) was predictive for a higher pathological complete response rate (odds ratio [OR] = 0.29; 95%CI = 0.14-0.61; p < 0.01).

Conclusion: In the present study, PLR was found as an independent prognostic factor for survival, while NLR was an independent predictive factor for febrile neutropenia.

Keywords: breast cancer; inflammatory blood marker; neoadjuvant chemotherapy; pathological complete response; predictive factor; prognostic factor.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492.
    1. Cortazar P., Geyer C.E. Pathological complete response in neoadjuvant treatment of breast cancer. Ann. Surg. Oncol. 2015;22:1441–1446. doi: 10.1245/s10434-015-4404-8.
    1. Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., Bonnefoi H., Cameron D., Gianni L., Valagussa P., et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014;384:164–172. doi: 10.1016/S0140-6736(13)62422-8.
    1. Nekljudova V., Loibl S., von Minckwitz G., Schneeweiss A., Glück S., Crane R., Li H., Luo X. Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC) Contemp. Clin. Trials. 2018;71:194–198. doi: 10.1016/j.cct.2018.06.016.
    1. Chen J., Deng Q., Pan Y., He B., Ying H., Sun H., Liu X., Wang S. Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer. FEBS Open Bio. 2015;5:502–507. doi: 10.1016/j.fob.2015.05.003.
    1. Faria S.S., Fernandes P.C., Silva M.J.B., Lima V.C., Fontes W., Freitas-Junior R., Eterovic A.K., Forget P. The neutrophil-to-lymphocyte ratio: A narrative review. Ecancermedicalscience. 2016;10:702. doi: 10.3332/ecancer.2016.702.
    1. Wei B., Yao M., Xing C., Wang W., Yao J., Hong Y., Liu Y., Fu P. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: An updated systematic review and meta-analysis. OncoTargets Ther. 2016;9:5567–5575. doi: 10.2147/OTT.S108419.
    1. Ethier J.-L., Desautels D., Templeton A., Shah P.S., Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: A systematic review and meta-analysis. Breast Cancer Res. 2017;19:2. doi: 10.1186/s13058-016-0794-1.
    1. Liu X., Qu J.-K., Zhang J., Yan Y., Zhao X.-X., Wang J.-Z., Qu H.-Y., Liu L., Wang J.-S., Duan X.-Y. Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis. Medicine. 2017;96:e8101. doi: 10.1097/MD.0000000000008101.
    1. Ou Q., Cheng J., Zhang L., Wang H., Wang W., Ma Y. The prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer: Deleterious or advantageous? Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2017;39:1010428317706214. doi: 10.1177/1010428317706214.
    1. Duan J., Pan L., Yang M. Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer: A meta-analysis. Medicine. 2018;97:e13340. doi: 10.1097/MD.0000000000013340.
    1. Xue L.B., Liu Y.H., Zhang B., Yang Y.F., Yang D., Zhang L.W., Jin J., Li J. Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: Meta-analysis. Medicine. 2019;98:e13842. doi: 10.1097/MD.0000000000013842.
    1. Li X., Dai D., Chen B., Tang H., Xie X., Wei W. The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. J. Cancer. 2018;9:861–871. doi: 10.7150/jca.23367.
    1. Chen Y., Chen K., Xiao X., Nie Y., Qu S., Gong C., Su F., Song E. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: A retrospective study. BMC Cancer. 2016;16:320. doi: 10.1186/s12885-016-2352-8.
    1. Cihan Y.B., Arslan A., Cetindag M.F., Mutlu H. Lack of Prognostic Value of Blood Parameters in Patients Receiving Adjuvant Radiotherapy for Breast Cancer. Asian Pac. J. Cancer Prev. 2014;15:4225–4231. doi: 10.7314/APJCP.2014.15.10.4225.
    1. Jia W., Wu J., Jia H., Yang Y., Zhang X., Chen K., Su F. The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients. PLoS ONE. 2015;10 doi: 10.1371/journal.pone.0143061.
    1. Eryilmaz M.K., Mutlu H., Salim D.K., Musri F.Y., Tural D., Coskun H.S. The Neutrophil to Lymphocyte Ratio has a High Negative Predictive Value for Pathologic Complete Response in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Asian Pac. J. Cancer Prev. 2014;15:7737–7740. doi: 10.7314/APJCP.2014.15.18.7737.
    1. Chae S., Kang K.M., Kim H.J., Kang E., Park S.Y., Kim J.H., Kim S.H., Kim S.W., Kim E.K. Neutrophil–lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer. Curr. Oncol. 2018;25:e113–e119. doi: 10.3747/co.25.3888.
    1. Hong J., Mao Y., Chen X., Zhu L., He J., Chen W., Li Y., Lin L., Fei X., Shen K. Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer. Tumor Biol. 2016;37:4135–4142. doi: 10.1007/s13277-015-4233-1.
    1. Graziano V., Grassadonia A., Iezzi L., Vici P., Pizzuti L., Barba M., Quinzii A., Camplese A., Di Marino P., Peri M., et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast. 2019;44:33–38. doi: 10.1016/j.breast.2018.12.014.
    1. Takeuchi H., Kawanaka H., Fukuyama S., Kubo N., Hiroshige S., Yano T. Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer. PLoS ONE. 2017;12 doi: 10.1371/journal.pone.0177137.
    1. Qian Y., Tao J., Li X., Chen H., Lu Q., Yang J., Pan H., Wang C., Zhou W., Liu X. Peripheral inflammation/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy. OncoTargets Ther. 2018;11:1423–1432. doi: 10.2147/OTT.S148496.
    1. Koh Y.W., Lee H.J., Ahn J.-H., Lee J.W., Gong G. Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. Tumor Biol. 2014;35:9823–9830. doi: 10.1007/s13277-014-2282-5.
    1. Noh H., Eomm M., Han A. Usefulness of Pretreatment Neutrophil to Lymphocyte Ratio in Predicting Disease-Specific Survival in Breast Cancer Patients. J. Breast Cancer. 2013;16:55–59. doi: 10.4048/jbc.2013.16.1.55.
    1. Nakano K., Hosoda M., Yamamoto M., Yamashita H. Prognostic Significance of Pre-treatment Neutrophil: Lymphocyte Ratio in Japanese Patients with Breast Cancer. Anticancer Res. 2014;34:3819–3824.
    1. Yao M., Liu Y., Jin H., Liu X., Lv K., Wei H., Du C., Wang S., Wei B., Fu P. Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. OncoTargets Ther. 2014;7:1743–1752. doi: 10.2147/OTT.S69657.
    1. Zhang P., Zong Y., Liu M., Tai Y., Cao Y., Hu C. Prediction of outcome in breast cancer patients using test parameters from complete blood count. Mol. Clin. Oncol. 2016;4:918–924. doi: 10.3892/mco.2016.827.
    1. Cho U., Park H.S., Im S.Y., Yoo C.Y., Jung J.H., Suh Y.J., Choi H.J. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. PLoS ONE. 2018;13:e0200936. doi: 10.1371/journal.pone.0200936.
    1. Geng S.-K., Fu S.-M., Fu Y.-P., Zhang H.-W. Neutrophil to lymphocyte ratio is a prognostic factor for disease free survival in patients with breast cancer underwent curative resection. Medicine. 2018;97 doi: 10.1097/MD.0000000000011898.
    1. Fujimoto Y., Ozawa H., Higuchi T., Miyagawa Y., Bun A., Imamura M., Miyoshi Y. Improved prognosis of low baseline neutrophil-to-lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes. Mol. Clin. Oncol. 2019;10:275–284. doi: 10.3892/mco.2018.1783.
    1. Qiu X., Song Y., Cui Y., Liu Y. Increased neutrophil–lymphocyte ratio independently predicts poor survival in non-metastatic triple-negative breast cancer patients. IUBMB Life. 2018;70:529–535. doi: 10.1002/iub.1745.
    1. Lee S.K., Choi M.-Y., Bae S.Y., Lee J.H., Lee H.-C., Kil W.H., Lee J.E., Kim S.W., Nam S.J. Immediate Postoperative Inflammation Is an Important Prognostic Factor in Breast Cancer. Oncology. 2015;88:337–344. doi: 10.1159/000368985.
    1. Kim Y.Y., Park H.K., Lee K.H., Kim K.I., Chun Y.S. Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer. J. Breast Cancer. 2016;19:163–168. doi: 10.4048/jbc.2016.19.2.163.
    1. Ramos-Esquivel A., Rodriguez-Porras L., Porras J. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in non-metastatic breast cancer patients from a Hispanic population. Breast Dis. 2017;37:1–6. doi: 10.3233/BD-160251.
    1. Vernieri C., Mennitto A., Prisciandaro M., Huber V., Milano M., Rinaldi L., Cona M.S., Maggi C., Ferrari B., Manoukian S., et al. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. Sci. Rep. 2018;8 doi: 10.1038/s41598-018-27075-z.
    1. Losada B., Guerra J.A., Malón D., Jara C., Rodriguez L., Del Barco S. Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients. Clin. Transl. Oncol. 2018 doi: 10.1007/s12094-018-1999-9.
    1. Suppan C., Bjelic-Radisic V., La Garde M., Groselj-Strele A., Eberhard K., Samonigg H., Loibner H., Dandachi N., Balic M. Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy. BMC Cancer. 2015;15 doi: 10.1186/s12885-015-2005-3.
    1. Marín Hernández C., Piñero Madrona A., Gil Vázquez P.J., Galindo Fernández P.J., Ruiz Merino G., Alonso Romero J.L., Parrilla Paricio P. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy. Clin. Transl. Oncol. 2018;20:476–483. doi: 10.1007/s12094-017-1732-0.
    1. Orditura M., Galizia G., Diana A., Saccone C., Cobellis L., Ventriglia J., Iovino F., Romano C., Morgillo F., Mosca L., et al. Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis. ESMO Open. 2016;1 doi: 10.1136/esmoopen-2016-000038.
    1. Forget P., Bentin C., Machiels J.-P., Berliere M., Coulie P.G., De Kock M. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br. J. Anaesth. 2014;113:i82–i87. doi: 10.1093/bja/aet464.
    1. Dirican A., Kucukzeybek B.B., Alacacioglu A., Kucukzeybek Y., Erten C., Varol U., Somali I., Demir L., Bayoglu I.V., Yildiz Y., et al. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer? Int J. Clin. Oncol. 2015;20:70–81. doi: 10.1007/s10147-014-0672-8.
    1. Pistelli M., De Lisa M., Ballatore Z., Caramanti M., Pagliacci A., Battelli N., Ridolfi F., Santoni M., Maccaroni E., Bracci R., et al. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer. 2015;15 doi: 10.1186/s12885-015-1204-2.
    1. Liu C., Huang Z., Wang Q., Sun B., Ding L., Meng X., Wu S. Usefulness of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hormone-receptor-negative breast cancer. OncoTargets Ther. 2016;9:4653–4660. doi: 10.2147/OTT.S106017.
    1. Cuello-López J., Fidalgo-Zapata A., López-Agudelo L., Vásquez-Trespalacios E. Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer. PLoS ONE. 2018;13 doi: 10.1371/journal.pone.0207224.
    1. Aapro M.S., Bohlius J., Cameron D.A., Dal Lago L., Donnelly J.P., Kearney N., Lyman G.H., Pettengell R., Tjan-Heijnen V.C., Walewski J., et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur. J. Cancer. 2011;47:8–32. doi: 10.1016/j.ejca.2010.10.013.
    1. Yamanouchi K., Kuba S., Sakimura C., Morita M., Kanetaka K., Kobayashi K., Takatsuki M., Hayashida N., Eguchi S. The Relationship between Peripheral Neuropathy Induced by Docetaxel and Systemic Inflammation-based Parameters in Patients with Breast Cancer. Anticancer Res. 2017;37:6947–6951.
    1. Ray-Coquard I., Ghesquière H., Bachelot T., Borg C., Biron P., Sebban C., LeCesne A., Chauvin F., Blay J.-Y. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br. J. Cancer. 2001;85:816–822. doi: 10.1054/bjoc.2001.2011.
    1. Ray-Coquard I., Borg C., Bachelot T., Sebban C., Philip I., Clapisson G., Le Cesne A., Biron P., Chauvin F., Blay J.Y. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br. J. Cancer. 2003;88:181–186. doi: 10.1038/sj.bjc.6600724.
    1. Choi C.W., Sung H.J., Park K.H., Yoon S.Y., Kim S.J., Oh S.C., Seo J.H., Kim B.S., Shin S.W., Kim Y.H., et al. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am. J. Hematol. 2003;73:263–266. doi: 10.1002/ajh.10363.
    1. Chen L., Zuo Y., Zhu L., Zhang Y., Li S., Ma F., Han Y., Song H., Xue Y. Peripheral venous blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. OncoTargets Ther. 2017;10:2569–2580. doi: 10.2147/OTT.S134716.
    1. Shen J., Zhu Y., Wu W., Zhang L., Ju H., Fan Y., Zhu Y., Luo J., Liu P., Zhou N., et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2017;23:315–324. doi: 10.12659/MSM.902752.
    1. Buisan O., Orsola A., Oliveira M., Martinez R., Etxaniz O., Areal J., Ibarz L. Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer with Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy. Clin. Genitourin. Cancer. 2017;15:e697–e706. doi: 10.1016/j.clgc.2017.01.024.
    1. Jacot W., Pouderoux S., Thezenas S., Chapelle A., Bleuse J.-P., Romieu G., Lamy P.-J. Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. Breast Cancer Res. Treat. 2012;134:709–717. doi: 10.1007/s10549-012-2084-7.
    1. Chiba A., Raman R., Thomas A., Lamy P.-J., Viala M., Pouderoux S., Mott S.L., Schroeder M.C., Thezenas S., Jacot W. Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer. Clin. Breast Cancer. 2018;18:144–149. doi: 10.1016/j.clbc.2017.12.001.
    1. Viala M., Chiba A., Thezenas S., Delmond L., Lamy P.-J., Mott S.L., Schroeder M.C., Thomas A., Jacot W. Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: A retrospective study. BMC Cancer. 2018;18:770. doi: 10.1186/s12885-018-4686-x.
    1. Fan Y.-S., Casas C.E., Peng J., Watkins M., Fan L., Chapman J., Ikpatt O.F., Gomez C., Zhao W., Reis I.M. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline. Breast Cancer Res. Treat. 2016;155:457–462. doi: 10.1007/s10549-016-3717-z.
    1. Hennequin C., Barillot I., Azria D., Belkacémi Y., Bollet M., Chauvet B., Cowen D., Cutuli B., Fourquet A., Hannoun-Lévi J.M., et al. Radiotherapy of breast cancer. Cancer Radiother. J. Soc. Francaise Radiother. Oncol. 2016;20:S139–S146. doi: 10.1016/j.canrad.2016.07.025.
    1. de Naurois J., Novitzky-Basso I., Gill M.J., Marti F.M., Cullen M.H., Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann. Oncol. 2010;21:v252–v256. doi: 10.1093/annonc/mdq196.
    1. Ferroni P., Roselli M., Buonomo O.C., Spila A., Portarena I., Laudisi A., Valente M.G., Pirillo S.P., Fortunato L., Costarelli L., et al. Prognostic Significance of Neutrophil–to–lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer. Anticancer Res. 2018;38:4705–4712. doi: 10.21873/anticanres.12777.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren